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Aims and methodology: the aim of this review is to provide an overview of the aetiology of neointima formation in vein
grafts and to highlight the use of an external support to modulate this phenomenon. A systematic literature review was
performed via computerised search on MEDLINE, OVID and the Cochrane Library. The search terms initially employed
were broad-based; `` vein graft'', `` neointima'' and `` external stent''. Subsequently, more specific search terms were utilised;
`` perivenous mesh'', `` external prosthesis'' and `` varicose vein''. Articles from indexed journals relevant to the objective,
external venous supports, from the earliest reports in the 1960's to the latest in 2001 were included to obtain an exhaustive
list. Reviews, abstracts and proceedings of scientific meetings, case reports and the results of both animal model investiga-
tions and human clinical trials in all languages were included. Articles describing an external support employed in both
peripheral and aortocoronary bypass investigations were included.
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Atherosclerosis is the single largest cause of death and
disablement in the western world.1 This generalised
arterial disease causes vessel narrowing and occlu-
sion, producing symptoms simultaneously in several
different sites. Coronary artery bypass grafting
(CABG) and infra-inguinal bypass surgery have revo-
lutionised the treatment of coronary artery occlusion
and critical lower-limb ischaemia respectively.2,3
Currently, over 24 000 CABG procedures and 20 000
peripheral bypass procedures are performed in the
U.K. per annum.4,5 Despite increased use of arterial
grafts in cardiac surgery, autologous saphenous vein
remains the predominant conduit for coronary artery
bypass grafting.2,6,7 Saphenous vein has been used to
bypass the femoropopliteal segment for over 50 years8
and is still the conduit of choice despite widespread
use of prosthetic grafts. Vein grafts confer significant
patency advantages over prosthetic grafts in bypasses
to both supra- and infra-geniculate regions.9±11Please address all correspondence to: V. Vijayan, Department
of Surgery, Vascular Studies Unit, Bristol Royal Infirmary,
Marlborough Street, Bristol, BS2 8HW, U.K.
1078±5884/02/010013  10 $35.00/0 # 2002 Elsevier Science Ltd. AHowever, long-term success of these interven-
tions is limited by progressive thickening of the vein
graft wall from intimal hyperplasia and eventually
superimposed atherosclerosis, resulting in symptom
recurrence12 (Fig. 1). 25±55% of infragenicular vein
grafts fail within 5 years of surgery13,14 and 47±74% of
venous coronary bypass grafts occlude within
10 years.15,16
Saphenous vein graft failure is one of the primary
reasons for CABG reoperation17 producing a huge
economic impact on Health Care resources and a
devastating effect on the individual. Up to 30% of
CABG procedures will require reoperation within
10 years to alleviate symptoms and treat vessel occlu-
sion18,19 and a third of all peripheral vascular opera-
tions are revisional.20 Secondary surgical procedures
carry significantly poorer prognosis than primary
operations and symptomatic relief is of shorter
duration.21,22
Aetiology of Vein Graft Neointima Formation
Neointima (NI) formation involves the migration and
proliferation of medial vascular smooth muscle cellsll rights reserved.
Fig. 1. Time-course of development of vein graft intimal hyperplasia and subsequent superimposed atherogenesis. Adapted from Jeremy
1997.12
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Fig. 2. Histological section of a porcine saphenous vein graft at
1 month. The arrowheads indicate the position of the internal elastic
lamina and the arrows the neointima. Note the degree of luminal
encroachment by the neointima.
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factors, across the internal elastic lamina to the intima,
resulting in graft wall thickening12 (Fig. 2). The aeti-
ology of NI formation is complex and multifactorial
and the precise initiating stimuli has not been fully
defined but it appears to be the response of the vas-
cular smooth muscle cells (VSMC) to a combination
of physical, cellular and humoral factors accom-
panied by dysfunctional endothelial regulation.23
Histological studies indicate that different sites along
the vein graft behave differently in accordance to
local haemodynamic characteristics and vein morph-
ology.24,25 Neointimal anastomotic stenosis is pro-
moted by anastomotic construction,26 turbulent flow
and deformation stress27,28 while intra-graft thick-
ening is related to vein quality, handling and pre-
existing abnormalities.29 Examining biological and
rheological characteristics of vein used as arterial
conduits allows insight into the possible causes of
intimal hyperplasia.
Vein quality
A correlation exists between the severity of pre-
existing pathological changes in vein grafts andsubsequent development of neointimal hyperpla-
sia.30,31 Intrinsic qualities of veins i.e. valves, tributaries,
varicosities and wall abnormalities have implications
for their utility as arterial conduits and are predictive
of poor outcome in arteriovenous bypass.32,33 The
persistence of valves and webs in the vein graft has
been postulated to act as `` pressure traps'' causing
turbulent blood flow and endothelial damage.34
Vein damage
The procedures involved in preparing veins for
bypass graft surgery (dissection, distension, storage
and anastomosis) illicit substantial physical damage
to the vein graft and denudation of the endothelium
which may contribute to the promotion of neointimal
hyperplasia.23,35,36 Arterial wall oxygenation occurs
by diffusion of oxygen out from the vessel lumen
and in from adventitial vasa vasorum. Studies show
that occlusion or denudation of the adventitia causes
focal lesions of intimal hyperplasia in vessel walls
with accumulation of cholesteryl esters.37,38
Haemodynamics
Autologous vein implanted into the arterial circula-
tion undergoes a characteristic sequence of adaptive
and pathological changes in response to the sudden
increase in intraluminal pressure and changes in
geometry.39 After implantation, the vein is exposed
to immediate increases in flow, longitudinal wall
shear stress, circumferential deformation and pulsa-
tile stress.40,41 Pulsatile stretch and increased shear
forces have direct effects on VSMC proliferation
and the production of endogenous growth factors
and on the synthesis of matrix components.42±44 Stud-
ies demonstrate that the ratio of luminal radius to wall
thickness in vein grafts tends to adapt to the
same value as that in the grafted artery, suggesting
that wall thickening occurs to normalise tangential
wall stress.45 The new geometry of end-to-side anasto-
moses causes increased turbulent flow with areas of
oscillating shear and stagnation at the distal anasto-
moses.24,25 These areas of disturbed flow form local-
ised vortices causing endothelial injury27 which
correlate with the preferential development of
intimal thickening at the hood of the graft and at the
distal suture line.46
Strategies to Reduce Neointima Formation
Avoidance of vessel wall injury during surgical
implantation reduces the marked inflammatoryEur J Vasc Endovasc Surg Vol 24, July 2002
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measures do not conclusively eliminate medial or
neointimal thickening.47 Apart from aggressive lipid
lowering therapy, pharmacological intervention has
hitherto proved unsuccessful in preventing late vein
graft failure.48 A variety of anti-platelet agents may
reduce early thrombotic occlusion in the first month
post CABG surgery49,50 and there is evidence that
aspirin improves long-term femoro-popliteal vein
graft patency.51±53 Many different therapeutic modal-
ities have been investigated in an attempt to control
NI formation. Pharmacological therapy with ACE
inhibitors54 and calcium channel antagonists,55 im-
munosuppression with cyclosporin,56 photodynamic
therapy employing laser light to promote apoptosis
in rapidly proliferating cells57 and even irradiation of
the vein graft prior to implantation58,59 have been
shown in animal models to be effective in reducing
intimal hyperplasia. The use of gene therapy in the
treatment of cardiovascular disease holds great prom-
ise.60 Vein grafts are particularly well suited for gene
transfer as direct access to the vein is available during
harvesting.61 Although promising, gene therapy
remains a largely experimental technique at this
time. In contrast, studies using prosthetic materials
as an external support around the vein graft have
proven an effective surgical intervention to reduce
neointimal hyperplasia and may potentially improve
long-term vein graft patency.
External Vein Graft Support
Early investigations
Parsonnet and colleagues were the first to report the
effect of an external sheath on vein grafts in 1963.
Loose-knit polypropylene-sheathed autologous vein
was interposed into the carotid artery of dogs to docu-
ment the effects that the sheath had on prevention of
dilatation and on its incorporation into the host's
tissue. The sheath was closely related to the adventitia
of the vein and the diameter of the graft could be
adjusted by varying the longitudinal tension. One
out of 25 sheathed grafts occluded in-situ. Within
a week the sheath became densely incorporated into
the host fibrous tissue and the sheath succeeded in
limiting venous over-distension of the arterialised
vein. Various uses for the sheath were proposed
including support of deeply endarterectomised
arteries, support of precarious anastomoses and wrap-
ping of composite vein grafts. However, no comment
on the biological reaction of the vein wall to the sheath
or effects on graft wall stress was made.62Eur J Vasc Endovasc Surg Vol 24, July 2002In 1978, the impact of the external sleeve on vein
wall thickening was realised by Karayannacos and
colleagues. Also in an attempt to reduce vein graft
over-distension, interposition grafts covered by either
a polyester mesh or a woven prosthesis were
implanted into the carotid circulation of dogs and
the effects on subendothelial cell proliferation stud-
ied. An important aspect of this study was the incorp-
oration of two subsets of stented veins, one with a
tight woven prosthesis and one with a loose-fitting
mesh. After 6 months in situ, unsupported grafts
had more subendothelial proliferation than those
with loose external mesh. The combined thickness of
the intima and media correlated inversely with the
number of vasa vasorum present in the vein graft
and significantly more vascularisation was found
in the looser stented vein graft.63 Another important
observation was that the increased porosity of the
loose-fitting mesh prosthesis allowed the vasa
vasorum to penetrate through the support to the
vein wall. This was the first description of the capacity
of an external stent to promote angiogenesis that
was believed to be interrelated to the development
of intimal hyperplasia.
Constrictive External Supports
Subsequent studies using restrictive PTFE or
DacronTM (polyester) external supports have yielded
mixed results, however. A tight mesh was favoured
because of its capacity to prevent over-distension of
the vein graft, which in turn, would limit subsequent
endothelial damage by adapting the venous graft
lumen to the diameter of the host artery.64 A polyester
mesh applied tightly to varicose veins to maintain a
uniform vein diameter after arterial implantation has
resulted in reasonable graft patencies in both sheep
and human studies.65±70 Pressure-resistant stainless
steel metal-mesh tubing has also been used to sheath
varicose veins to reduce tangential forces and non-
uniform distension and has been shown to reduce
neointima formation in porcine models.71 Tight-fitting
polyethylene tubes placed around interposed rat veins
have successfully limited arterialisation expansion
and regulate the turbulent flow of blood by equalising
the diameter along the vein graft.72 The placement of
tight-fitting PTFE stents around vein grafts in rabbit
models of arteriovenous bypass have resulted in a
reduction in intimal thickening, vessel cross-sectional
area and smooth muscle cell volume.73±76 However,
Violaris found in the pig saphenous vein graft model,
that placement of a restrictive PTFE stent resulted in
an increase in intimal thickening and luminal
A B
Fig. 3. Schematic representation of porcine saphenous vein graft
interposed into common carotid artery. A ± no external support;
B ± with external support.
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ness.77 Constrictive external prostheses reduce the
vein graft's elasticity and by limiting expansion
increase mean shear stress. However, constrictive
stents, either polyester, PTFE or metal mesh, potential-
ly cause interruption of the adventitial vasa vasorum
promoting ischaemic damage to the graft walls, recog-
nised as a stimulus for neointima formation.37,78,79
Loose fitting external supports
More recently, non-restrictive polyester mesh tubes
with a helical polypropylene support, have been
shown to produce remarkable reductions in both
medial and intimal hyperplasia.80 These loose-fitting,
highly porous external stents initially allow unres-
tricted expansion of the vein as a response to arterial
pressure, and then gradually become incorporated
into a `` neoadventia'' surrounding the vein graft.
Importantly, the improvements in luminal cross-
sectional area and reductions in medial and intimal
thickening persist regardless of stent size.81 This obvi-
ates the need for precise matching of vein diameter
to a loose stent and simplifies the surgical procedure
without compromising biological benefit. As the vein
expands, the extra-luminal thrombus that exists
between the stent and adventitia gradually becomes
organised and the stent becomes integrated into the
graft wall. Reduction in neointima development has
been shown to continue for some time after stent
implantation, with a persistent beneficial effect at six
months.82 These investigations have been performed
on an established porcine model of arteriovenous
bypass and they all involve end-to-end interposition
vein grafting (Fig. 3). Recently, the clinically analogous
end-to-side model incorporating over-sized polyester
stents as utilised by Bulbulia and colleagues has also
been shown to produce a reduction in neointimal
and medial thickness.83
Biodegradable external supports
The use of a biodegradable external stent as a tempor-
ary protective scaffold has also been investigated.
Employment of a biodegradable material represents
an attempt to limit potential long-term deleterious
effects of prosthetic material such as chronic inflam-
mation, infection,84 seroma accumulation, perigraft
fibrosis, graft constriction and mechanical problems.
Temporary protection of autologous vein grafts
against over-distension has been achieved using
compliant synthetic biodegradable external stents inrabbits,85±88 which allowed improved preservation of
smooth muscle cell layers, elastic laminae and the
architectural integrity of the vein wall. It was observed
that degradation of the prosthesis must occur in con-
cert with vein graft arterialisation to allow optimal
readjustment of the radius and thickness of the
graft wall. Loose-fitting VicrylTM (polyglactin) stents
have also been used in porcine models resulting in
preservation of vascular endothelium and reduction
in medial thickness.89 It has been noted that biodeg-
radation of the stent material incites significant
macrophage infiltration into the media.90 This phe-
nomenon raises questions as to the effect of macro-
phage activity on extracellular matrix remodelling,
cell proliferation and neointima formation.
Human trials of the external support
Despite ongoing research for the ideal prosthetic
material, the external venous support has been uti-
lised in human surgery for over a decade. Barra was
the first to implant saphenous vein grafts surrounded
by constrictive mesh into the coronary circulation of
four patients, with angiographic evidence of patency
at two months.64 In the mid-80's, Deriu and collea-
gues described utilising reinforced PTFE in 30 human
arterial reconstructive procedures to protect vein
bypass grafts from positional kinking and external
compression by anatomical structures.91 Histological
finding at post-mortem showed an arterialised veinEur J Vasc Endovasc Surg Vol 24, July 2002
Fig. 4. Photomicrograph of trichrome-stained section of a porcine
vein graft fitted with a porous loose-fitting external sleeve one
month after implantation. The large arrowheads indicate where
the sleeve material begins and the arrows the media. Note the
absence of a neointima. In the region between the sleeve and
media is a highly organised neoadventitia which is infiltrated with
new vessels of different sizes.
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the PTFE was incorporated into the anastomoses, no
mention of the effect of the support on distal anasto-
motic intimal hyperplasia was described. Varicose
and ectatic veins are deemed unsuitable for arterial
bypass due to their unfavourable flow dynamics and
their high failure rate.92,93 However, varicose veins
sheathed with calibrated polyester mesh have been
used in both infra inguinal and coronary artery bypass
procedures to avoid the use of vascular prostheses
with good graft performance in the initial clinical ser-
ies but no long-term data of their effects have been
described.70,94,95 The biocompound graft (varicose
vein supported by metal mesh and fibrin sealant)
has been employed effectively for both femoropopli-
teal bypass and in over 950 CABG procedures world-
wide with a patency rate similar to saphenous vein.96
The biocompound graft offers surgeons the possibility
of using ectatic varicose veins as a reliable conduit if
alternative bypasses are not available97 but the experi-
mental findings of the metal mesh support reducing
intima formation has so far not been documented in
humans. Saphenous vein covered with a ring-
enforced artificial vascular graft made of Gor-TexTM
has been utilised by neurosurgeons to prevent exter-
nal compression of bypass grafts within the cra-
nium.98 Again, the effect on neointima formation is
known only from experimental animal models.
Mechanism of Action of the External Support
The pathophysiological mechanisms underlying the
capacity of the external stent to limit neointima for-
mation is not completely understood, however, sev-
eral hypotheses based on observation and vascular
biological principles have been proposed.
Haemodynamic modulation
Sudden exposure to increased shear forces and tan-
gential stresses within the arterial system initiate mor-
phological changes in vein grafts, which ultimately
lead to the development of medial and intimal thick-
ening.45,75 Theoretically, by reducing wall tension and
cyclical deformation, the placement of an external
support may result in a reduction of adaptive graft
thickening. Thus, various attempts have been made
to attenuate wall tension and cyclical deformation
in venous graft walls through the use of constrictive
external prostheses to prevent over-distension and
equalise the diameter of the arterialised vein graft
along its length. This reduction of distension regulatesEur J Vasc Endovasc Surg Vol 24, July 2002turbulent flow along the lumen, reducing the risk of
endothelial damage and mural thrombus.64,72 By nar-
rowing the vessel lumen, by Pouiseille's Law, the
blood flow velocity increases through the supported
segment of vein which reduces circumferential stres-
ses, but concomitantly increases the shear stresses at
the endothelial surface.62,75 There is evidence that
increased rate of blood flow through grafts results
in a reduction in VSMC number, thus reducing the
cross-sectional area of neointima.99,100 However, the
prevention of distension with restrictive non-porous
external stents has been shown to be detrimental,
actually promoting neointimal formation and ultim-
ately luminal narrowing.37,78 Loose-fitting external
supports, in comparison, are initially not in direct
contact with the vein wall and a fibrin-rich exudate
forms in the space between the graft and the stent.82
Microvessels grow rapidly into this exudate and
fibroblasts proliferate to form a highly organised
`` neoadventitia'' (Fig. 4). This process can be likened
to wound healing; the thrombus organises and
becomes vascular, cellular granulation tissue and
then forms scar tissue.82 With the development of
this `` neoadventitia'', the stent becomes continuous
with the graft wall, and as such is likely to mechan-
ically unload the vein wall, limiting tangential and
circumferential deforming forces of pulsatile
stretch73,94,95 and may consequently attenuate early
changes in gene expression, reducing intimal and
medial thickening.39
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The placement of an external support is thought to
stimulate a `` foreign body'' type reaction with acti-
vation of a localised inflammatory cascade and stimu-
lation of angiogenesis. Highly porous, loose-fitting
external sheaths have improved success in limiting
neointimal hyperplasia63,81,93,94 as they promote the
formation of a `` neovasa vasorum'', which reduces
medial hypoxia. The placement of a constrictive non-
porous silastic cuff has been used as a model for
arterial intimal hyperplasia since it prevents flow
through the adventitial vasa vasorum which has
been suggested to provoke intimal thickening
through hypoxia-induced production of mitogenic
factors.37,78,101 Non-restrictive supports do not oc-
clude the vasa vasorum and also have a minimal effect
on transmural fluid flux and thus decreasing the
concentration of locally produced growth factors
and lipoproteins around the graft.
Polyester velour incorporates loops of yarn
which extend out into the fibrous tissue and these
may stimulate the development of an adventitial
inflammatory reaction, facilitating the formation of
the `` neovasa vasorum''.102 Microvessels seen in asso-
ciation with the polyester sheath are larger and more
fully developed extending through the prosthesis
into the intimal/medial interface. It can be conclu-
ded that the highly vascular network evoked by the
polyester support may improve oxygenation and
nutrient supply to the vessel wall, in turn preventing
hypoxic damage and oxidative stress. In contrast, the
adventitia surrounding unstented vessels is diffuse
and poorly organised. This may also account for the
inverse relationship between stent size and neointimal
thickening.63,81 A constrictive stent is far more likely
to cause adventitial disruption and limit angiogenesis.
Growth factors and cytokines
Another feature of the polyester external support in
the porcine vein graft model is a marked association of
immune and inflammatory cells (neutrophils, macro-
phages, lymphocytes, T-cells and giant cells). These
cells had accumulated in the interstices of the macro-
porous prosthesis.82,102 Comparison of materials indi-
cate that macroporous, non-restrictive polyester mesh
results in a significantly larger reduction of neointimal
thickening than microporous non-restrictive PTFE.102
Notably, cellular infiltration was reduced in the PTFE
loose fitting support. This consolidates that porosity is
an absolute requirement for the external stent to
be effective.63,95 Since these cells release a battery ofchemoattractant factors for VSMC, it has been postu-
lated that instead of medial VSMCs migrating to the
intima they migrate toward the external synthetic sup-
port itself.102 The external support-leukocyte complex
sets up a `` reverse'' chemokine gradient that promotes
migration of VSMC's away from the lumen of the
vessel, out towards the periphery. Immunocytochem-
ical analysis has shown a significant increase in
platelet-derived growth factor expression in the
media of externally stented vein.102 Prostacyclin, nitric
oxide, cyclic AMP and cyclic GMP formation, all inhi-
bitors of VSMC proliferation and migration, were also
shown to be augmented by the polyester support in
the same porcine model.103 It has been demonstrated
in porcine vein grafts not fitted with external supports
that there is a dramatic increase in perivascular
(medial) nerves and a striking growth of nerve bun-
dles within the adventitia104 which was prevented by
the external polyester support.105 The pathological
implications of this effect, however, have not been
defined but many classical neurotransmitters also pro-
mote cellular proliferation and thus this `` neoinnerva-
tion'' of may promote neointima formation.
Summary and the Future
Autologous saphenous vein remains the most widely
used conduit for both aortocoronary bypass and lower
limb salvage, despite its relatively poor long-term
patency rate. Vessel wall thickening may be regarded
as an intrinsic adaptation of the vein to arterial pres-
sure and thus a degree of hyperplasia must be
accepted. However, whether the vein stabilises or
progresses to significant interference with flow is
largely determined by the local physical and metab-
olic environment.106
Currently, constrictive external sheaths are
employed principally to utilise autologous ectatic
veins but the effect on human NI formation is
unknown. The long-term effects of the sheath in
hypercholesterolaemic and diabetic patients and
the effects of decades of constant movement of sup-
ported vessels are also unknown. Prosthetic material
implanted into tissue has its own potential compli-
cations; hypersensitivity reactions, inflammation and
infection. A biodegradable stent that confers benefit
and then disappears is a plausible concept but
therein too lies uncertainty. Biological effects of bio-
degradation on the vessel wall and surrounding tis-
sue require investigation. The type of material,
synthetic versus biological and the optimal half-life
of biodegradation are all topics for further research.
Further investigation into the mechanisms of actionEur J Vasc Endovasc Surg Vol 24, July 2002
20 V. Vijayan et al.of the external sleeve needs to be undertaken espe-
cially its angiogenic effects. The clinical difficulties
in incorporating the external sheath around complex
distal peripheral anastomoses or around coronary
arteries deeply embedded in myocardium needs to
be addressed.
The application of a loose fitting, macroporous,
external support in the porcine model has consistently
been proven to attenuate vessel wall distension,
increase the total luminal area and reduce neointimal
hyperplasia. However, although loose fitting poly-
ester support is applicable to human saphenous vein
grafts, the innate dangers of extrapolating from ani-
mal models to man are well recognised and further
clinical trials are necessary prior to advocating its
widespread use in human surgery. Armed with ever
increasing knowledge of vascular biology we need
to devise strategies to improve late vein graft failure.
The outcome of further work involving trials of exter-
nally supported vein grafts is awaited.
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